Udenafil: Efficacy and tolerability in the management of erectile dysfunction

Sung-Gu Kang, Je-Jong Kim

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalTherapeutic Advances in Urology
Volume5
Issue number2
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

udenafil
Erectile Dysfunction
Phosphodiesterase 5 Inhibitors
Phosphoric Diester Hydrolases
Korea
Hyperplasia
Prostate
Diabetes Mellitus

Keywords

  • Erectile dysfuction
  • Once-daily dosing
  • Phosphodiesterase type 5
  • Udenafil

ASJC Scopus subject areas

  • Urology

Cite this

Udenafil : Efficacy and tolerability in the management of erectile dysfunction. / Kang, Sung-Gu; Kim, Je-Jong.

In: Therapeutic Advances in Urology, Vol. 5, No. 2, 01.01.2013, p. 101-110.

Research output: Contribution to journalReview article

@article{c2d16a7adb1648d19112547b5e296000,
title = "Udenafil: Efficacy and tolerability in the management of erectile dysfunction",
abstract = "Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.",
keywords = "Erectile dysfuction, Once-daily dosing, Phosphodiesterase type 5, Udenafil",
author = "Sung-Gu Kang and Je-Jong Kim",
year = "2013",
month = "1",
day = "1",
doi = "10.1177/1756287212470019",
language = "English",
volume = "5",
pages = "101--110",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Udenafil

T2 - Efficacy and tolerability in the management of erectile dysfunction

AU - Kang, Sung-Gu

AU - Kim, Je-Jong

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.

AB - Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.

KW - Erectile dysfuction

KW - Once-daily dosing

KW - Phosphodiesterase type 5

KW - Udenafil

UR - http://www.scopus.com/inward/record.url?scp=84876376281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876376281&partnerID=8YFLogxK

U2 - 10.1177/1756287212470019

DO - 10.1177/1756287212470019

M3 - Review article

C2 - 23554845

AN - SCOPUS:84876376281

VL - 5

SP - 101

EP - 110

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 2

ER -